Patents by Inventor Christine A. Fazenbaker

Christine A. Fazenbaker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-STEAP2 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20230192803
    Abstract: The disclosure provides chimeric antigen receptors and antibodies that comprise antigen-binding domains that specifically bind human STEAP2, nucleotides that encode the same, cells comprising the same, and methods of using the same in the treatment of cancer (e.g., prostate cancer).
    Type: Application
    Filed: October 14, 2022
    Publication date: June 22, 2023
    Inventors: Emily BOSCO, Dewald VAN DYK, Gordon MOODY, Christine FAZENBAKER, Chien-ying CHANG
  • Methods for the administration of amifostine and related compounds
    Patent number: 7678779
    Abstract: The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy or chemotherapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.
    Type: Grant
    Filed: February 20, 2008
    Date of Patent: March 16, 2010
    Assignee: MedImmune, LLC
    Inventors: David Cassatt, Christine A. Fazenbaker
  • Methods for the administration of amifostine and related compounds
    Publication number: 20080207566
    Abstract: The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy or chemotherapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.
    Type: Application
    Filed: February 20, 2008
    Publication date: August 28, 2008
    Inventors: David Cassatt, Christine A. Fazenbaker
  • Methods for the administration of amifostine and related compounds
    Patent number: 7368440
    Abstract: The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy or chemotherapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: May 6, 2008
    Assignee: Medimmune Oncology, Inc.
    Inventors: David Cassatt, Christine A. Fazenbaker
  • Methods for the administration of amifostine and related compounds
    Publication number: 20060128672
    Abstract: The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy or chemotherapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.
    Type: Application
    Filed: February 8, 2006
    Publication date: June 15, 2006
    Inventors: David Cassatt, Christine Fazenbaker
  • Methods for the administration of amifostine and related compounds
    Patent number: 7053072
    Abstract: The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: May 30, 2006
    Assignee: Medimmune Oncology, Inc.
    Inventors: David Cassatt, Christine A. Fazenbaker
  • Methods for the administration of amifostine and related compounds
    Publication number: 20030139323
    Abstract: The present invention provides methods of administering amifostine, WR-1065, or a combination thereof, to patients receiving radiation therapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.
    Type: Application
    Filed: May 8, 2002
    Publication date: July 24, 2003
    Inventors: David Cassatt, Christine A. Fazenbaker